Osaka, Japan

Yuki Tachibana

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2012-2023

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Yuki Tachibana: Innovator in Pharmaceutical Chemistry

Introduction

Yuki Tachibana is a prominent inventor based in Osaka, Japan, known for her significant contributions to pharmaceutical chemistry. With a total of six patents to her name, she has made remarkable advancements in the field, particularly in developing compounds with therapeutic applications.

Latest Patents

Among her latest patents is a groundbreaking invention involving triazine derivatives that exhibit virus replication inhibitory activity. This invention provides a compound that demonstrates inhibitory activity against the coronavirus 3 CL protease, along with a pharmaceutical composition that includes this compound. Additionally, she has developed a crystalline form that serves as an active pharmaceutical ingredient. Another notable patent is for a sulfonamide derivative that possesses PGD2 receptor antagonistic activity, which is aimed at treating allergic diseases.

Career Highlights

Yuki Tachibana has worked with esteemed organizations such as Shionogi & Company Limited and Hokkaido University. Her work in these institutions has allowed her to focus on innovative research and development in the pharmaceutical sector.

Collaborations

Throughout her career, Yuki has collaborated with notable colleagues, including Akira Kugimiya and Masahiko Fujioka. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Yuki Tachibana's contributions to pharmaceutical chemistry through her innovative patents and collaborations highlight her role as a leading inventor in her field. Her work continues to impact the development of therapeutic agents, showcasing the importance of innovation in addressing health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…